import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "ghrp-comparison-complete-research-guide",
  title: "GHRP-2 vs GHRP-6 vs Hexarelin vs Ipamorelin: The Complete Research Comparison",
  description:
    "A head-to-head comparison of the four major growth hormone releasing peptides (GHRPs) studied in research. Covers receptor selectivity, GH pulse magnitude, side effect profiles, desensitization rates, and protocol design implications.",
  category: "Compound Profiles",
  readMinutes: 11,
  publishedAt: "2026-06-07",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Growth Hormone Releasing Peptides (GHRPs) are a family of synthetic peptides that act as agonists at the Growth Hormone Secretagogue Receptor (GHSR-1a), stimulating pulsatile GH release from the pituitary gland. Since the discovery of GHRP-6 in the early 1980s, the class has expanded to include GHRP-2, Hexarelin, and Ipamorelin — each with a distinct profile of potency, selectivity, side effect characteristics, and desensitization behavior.",
    },
    {
      type: "paragraph",
      text: "This article provides a direct head-to-head comparison of all four GHRPs based on the published preclinical and clinical research literature.",
    },
    {
      type: "heading",
      text: "The GHRP Class: Shared Mechanism, Different Profiles",
    },
    {
      type: "paragraph",
      text: "All four GHRPs share a common primary mechanism: agonism at the GHSR-1a receptor in the hypothalamus and anterior pituitary. This receptor is the endogenous target of ghrelin — the 'hunger hormone' produced in the stomach — and its activation triggers GH pulse release. The synthetic GHRPs were developed to reproduce or enhance this effect with greater stability and potency than native ghrelin.",
    },
    {
      type: "paragraph",
      text: "Where the compounds diverge is in their off-target receptor interactions. GHSR-1a is not the only receptor these peptides interact with at relevant concentrations, and the additional receptor engagements produce the differences in side effect profiles, appetite stimulation, cortisol/prolactin elevation, and cardiac effects that distinguish the four compounds in research.",
    },
    {
      type: "heading",
      text: "GHRP-6: The Original",
    },
    {
      type: "paragraph",
      text: "GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) was the first synthetic GHRP characterized and remains a reference compound in the field. Its GH-releasing potency is moderate relative to later-generation GHRPs, but its off-target profile is the broadest of the four — which has made it both scientifically interesting and practically limiting for certain research applications.",
    },
    {
      type: "subheading",
      text: "Key Characteristics",
    },
    {
      type: "list",
      items: [
        "GH pulse magnitude: Moderate (significant but lower than GHRP-2 or Hexarelin per molar dose)",
        "Appetite stimulation: Strong — GHRP-6 robustly activates ghrelin-associated orexigenic pathways; a significant confound in metabolic research",
        "Cortisol/ACTH elevation: Moderate — documented in human studies; less pronounced than Hexarelin",
        "Prolactin elevation: Mild to moderate",
        "Desensitization rate: Moderate — receptor downregulation documented with frequent administration",
        "Half-life: ~15–20 minutes — very short, necessitating frequent dosing",
      ],
    },
    {
      type: "paragraph",
      text: "GHRP-6's strong appetite stimulation has made it useful for studying ghrelin-pathway feeding behavior and body composition in rodent models, but it complicates protocols where researchers want to isolate GH axis effects from appetite and caloric intake changes. Its role in contemporary research has diminished as more selective compounds became available.",
    },
    {
      type: "heading",
      text: "GHRP-2: Higher Potency, Similar Caveats",
    },
    {
      type: "paragraph",
      text: "GHRP-2 (D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2) was developed as a second-generation GHRP with enhanced GHSR-1a potency relative to GHRP-6. Molar-for-molar, GHRP-2 produces larger GH pulses in most studied models.",
    },
    {
      type: "subheading",
      text: "Key Characteristics",
    },
    {
      type: "list",
      items: [
        "GH pulse magnitude: High — among the most potent GH-releasing agents in the GHRP class",
        "Appetite stimulation: Moderate — less orexigenic than GHRP-6 but still present",
        "Cortisol/ACTH elevation: Moderate — documented in clinical studies; cortisol co-elevation is a design consideration in stress-axis research",
        "Prolactin elevation: Mild — somewhat less than GHRP-6",
        "Desensitization rate: Moderate to high with frequent dosing",
        "Half-life: ~15–20 minutes",
      ],
    },
    {
      type: "paragraph",
      text: "GHRP-2 has been used in clinical research as a diagnostic tool for GH deficiency assessment, leveraging its reliable and robust GH-releasing effect. The GH stimulation test using GHRP-2 + GHRH (often Sermorelin or CJC-1295) produces near-maximal GH pulses and has been studied as a pituitary function evaluation protocol.",
    },
    {
      type: "heading",
      text: "Hexarelin: Maximum Potency, Maximum Side Effects",
    },
    {
      type: "paragraph",
      text: "Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is the most potent GHRP in terms of GH release magnitude at equivalent doses, but carries the most pronounced off-target effects of the class. Its research history includes a notable and unexpected finding: direct cardiac receptor activity independent of GH release.",
    },
    {
      type: "subheading",
      text: "Key Characteristics",
    },
    {
      type: "list",
      items: [
        "GH pulse magnitude: Highest of the four GHRPs at equivalent doses",
        "Appetite stimulation: Moderate",
        "Cortisol/ACTH elevation: High — the most pronounced cortisol co-elevation of the class; significant confounder for HPA axis research",
        "Prolactin elevation: Moderate to high — the most significant prolactin response of the four GHRPs",
        "Desensitization rate: High — Hexarelin is well-documented to produce rapid and pronounced GHSR tachyphylaxis with continued use; this has been a significant limiting factor in research applications",
        "Cardiac receptor activity: Unique among GHRPs — Hexarelin binds a cardiac-specific receptor (CD36) independent of GHSR-1a, producing direct cardioprotective effects in ischemia/reperfusion models",
        "Half-life: ~30 minutes",
      ],
    },
    {
      type: "paragraph",
      text: "Hexarelin's cardiac receptor binding is its most scientifically distinctive feature. Studies by Mericq et al., Locatelli et al., and the group at the University of Milan documented Hexarelin's cardioprotective effects in rat cardiac ischemia models — an effect not seen with other GHRPs and not blocked by GH receptor antagonism, confirming it is GH-independent. This has made Hexarelin the subject of separate cardiac research programs from its GH-related use.",
    },
    {
      type: "paragraph",
      text: "Its high desensitization rate means long-duration GH axis research protocols with Hexarelin require careful management of dosing intervals or washout periods to maintain receptor sensitivity across the study window.",
    },
    {
      type: "heading",
      text: "Ipamorelin: The Selective Third Generation",
    },
    {
      type: "paragraph",
      text: "Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) was specifically designed to address the off-target limitations of earlier GHRPs. Its defining characteristic is high selectivity for GHSR-1a with minimal activity at other receptors — resulting in GH release without significant cortisol, prolactin, or appetite effects.",
    },
    {
      type: "subheading",
      text: "Key Characteristics",
    },
    {
      type: "list",
      items: [
        "GH pulse magnitude: High — comparable to GHRP-2, somewhat less than Hexarelin per molar dose",
        "Appetite stimulation: Minimal to absent — major advantage over GHRP-6",
        "Cortisol/ACTH elevation: Minimal — documented absence of cortisol co-elevation at effective GH-releasing doses; major advantage over all other GHRPs",
        "Prolactin elevation: Minimal — similar to cortisol; largely absent at research doses",
        "Desensitization rate: Low — Ipamorelin produces less GHSR tachyphylaxis than other GHRPs; more suitable for sustained research protocols",
        "Half-life: ~2 hours — significantly longer than other GHRPs, reducing dosing frequency requirements",
      ],
    },
    {
      type: "paragraph",
      text: "Ipamorelin's selectivity profile makes it the preferred GHRP for research applications where isolating GH axis effects is the priority — it provides robust GH pulse stimulation without the cortisol, prolactin, and appetite confounders that complicate interpretation with older GHRPs. Its longer half-life also improves practical study design by allowing twice-daily rather than three-times-daily administration.",
    },
    {
      type: "heading",
      text: "Head-to-Head Comparison",
    },
    {
      type: "table",
      headers: ["Property", "GHRP-6", "GHRP-2", "Hexarelin", "Ipamorelin"],
      rows: [
        ["GH Release Potency", "Moderate", "High", "Highest", "High"],
        ["Cortisol Elevation", "Moderate", "Moderate", "High", "Minimal"],
        ["Prolactin Elevation", "Mild-Moderate", "Mild", "Moderate-High", "Minimal"],
        ["Appetite Stimulation", "Strong", "Moderate", "Moderate", "Minimal"],
        ["Desensitization Rate", "Moderate", "Moderate-High", "High", "Low"],
        ["Cardiac Activity", "None", "None", "Yes (CD36)", "None"],
        ["Half-Life", "~15-20 min", "~15-20 min", "~30 min", "~2 hrs"],
        ["Research Selectivity", "Low", "Moderate", "Low (high potency)", "High"],
      ],
    },
    {
      type: "heading",
      text: "Synergy with GHRH Analogs",
    },
    {
      type: "paragraph",
      text: "All four GHRPs produce significantly amplified GH pulses when co-administered with GHRH analogs (CJC-1295, Sermorelin, Tesamorelin). The combination acts synergistically because GHRH operates through a different receptor (GHRH-R) and primes the pituitary for larger GH release — while the GHRP provides the primary stimulatory signal through GHSR-1a.",
    },
    {
      type: "paragraph",
      text: "In combination protocols, Ipamorelin + CJC-1295 (no-DAC) has become the most widely studied pairing in current research due to Ipamorelin's selectivity advantage and CJC-1295 no-DAC's short half-life enabling pulsatile administration. The combination achieves GH pulse amplitudes comparable to exogenous GH while preserving the pulsatile rhythm of the natural GH axis — a significant mechanistic distinction that matters for endpoints involving GH receptor desensitization, IGF-1 regulation, and downstream tissue effects.",
    },
    {
      type: "heading",
      text: "Choosing a GHRP for Research",
    },
    {
      type: "paragraph",
      text: "Compound selection should be driven by the research question. If the goal is to study pure GH axis effects without confounds, Ipamorelin is the logical choice for its selectivity and low desensitization rate. If cardiac receptor biology is the focus, Hexarelin is the only GHRP that accesses CD36 and is the appropriate tool. If appetite-GH interaction is the study question, GHRP-6 provides the most robust orexigenic confound to explore.",
    },
    {
      type: "paragraph",
      text: "Historical reference compounds (GHRP-6 and GHRP-2) remain relevant for studies that need to be comparable to existing literature — many published protocols used these compounds, and reproducing prior results for validation requires using the same compound. For new protocol design without historical constraints, Ipamorelin's superior selectivity profile makes it the contemporary default.",
    },
    {
      type: "divider",
    },
    {
      type: "disclaimer",
      text: "For research purposes only. Not intended for human use. All data reflects preclinical and early clinical research literature. Compounds discussed are not approved for human therapeutic use.",
    },
  ],
};
